ZEKLEN 10 mg/80 mg ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

zeklen 10 mg/80 mg ezetimibe 10 mg and simvastatin 80 mg tablet blister pack

organon pharma pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 80 mg - tablet, uncoated - excipient ingredients: magnesium stearate; butylated hydroxyanisole; lactose monohydrate; hypromellose; microcrystalline cellulose; croscarmellose sodium; propyl gallate; citric acid monohydrate - adults (greater than or equal to 18 years),prevention of cardiovascular disease,zeklen is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties, clinical trials).,primary hypercholesterolaemia,zeklen is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,- patients not appropriately controlled with a statin or ezetimibe alone.,- patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),zeklen is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,children and adolescents 10-17 years,(pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),zeklen is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,- patients not appropriately controlled with a statin or ezetimibe alone.,- patients already treated with a statin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),zeklen is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

EZETORIN 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ezetorin 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack

torrent australasia pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 80 mg - tablet - excipient ingredients: croscarmellose sodium; propyl gallate; microcrystalline cellulose; ascorbic acid; magnesium stearate; butylated hydroxyanisole; hypromellose; citric acid monohydrate; lactose monohydrate; ferric oxide - adults (greater than or equal to 18 years),prevention of cardiovascular disease,ezetorin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,ezetorin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetorin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezetorin is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetorin is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

APO-EZETIMIBE/SIMVASTATIN 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-ezetimibe/simvastatin 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack

torrent australasia pty ltd - simvastatin, quantity: 80 mg; ezetimibe, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; propyl gallate; croscarmellose sodium; butylated hydroxyanisole; ascorbic acid; citric acid monohydrate; microcrystalline cellulose; hypromellose; magnesium stearate; ferric oxide - adults (greater than or equal to 18 years),prevention of cardiovascular disease,apo-ezetimine/simvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,apo-ezetimine/simvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),apo-ezetimine/simvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),apo-ezetimine/simvastatin is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),apo-ezetimine/simvastatin is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

NNA-EZETIMIBE/SIMVASTATIN 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

nna-ezetimibe/simvastatin 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack

arrotex pharmaceuticals pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 80 mg - tablet - excipient ingredients: lactose monohydrate; citric acid; magnesium stearate; iron oxide yellow; propyl gallate; hypromellose; iron oxide red; butylated hydroxyanisole; microcrystalline cellulose; croscarmellose sodium; iron oxide black; ascorbic acid - adults (?18 years),prevention of cardiovascular disease apo-ezetimibe/simvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials).,primary hypercholesterolaemia apo-ezetimibe/simvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) apo-ezetimibe/simvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis). children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post- menarche),heterozygous familial hypercholesterolaemia (hefh) apo-ezetimibe/simvastatin is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) apo-ezetimibe/simvastatin is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

EzSimva GH 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ezsimva gh 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack

torrent australasia pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 80 mg - tablet - excipient ingredients: citric acid monohydrate; hypromellose; croscarmellose sodium; butylated hydroxyanisole; propyl gallate; lactose monohydrate; microcrystalline cellulose; magnesium stearate; ferric oxide; ascorbic acid - adults (greater than or equal to 18 years),prevention of cardiovascular disease,ezsimva gh is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,ezsimva gh is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezsimva gh s is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezsimva gh is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezsimva gh is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

SIMTORSI 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

simtorsi 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack

torrent australasia pty ltd - simvastatin, quantity: 80 mg; ezetimibe, quantity: 10 mg - tablet - excipient ingredients: butylated hydroxyanisole; microcrystalline cellulose; ascorbic acid; ferric oxide; citric acid monohydrate; hypromellose; magnesium stearate; lactose monohydrate; propyl gallate; croscarmellose sodium - adults (greater than or equal to 18 years),prevention of cardiovascular disease,simtorsi is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,simtorsi is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),simtorsi is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

VYTORIN 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

vytorin 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack

organon pharma pty ltd - simvastatin, quantity: 80 mg; ezetimibe, quantity: 10 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; propyl gallate; magnesium stearate; citric acid monohydrate; hypromellose; lactose monohydrate; butylated hydroxyanisole - adults (greater than or equal to 18 years) prevention of cardiovascular disease vytorin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials).,primary hypercholesterolaemia vytorin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) vytorin is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Ezetimibe/Simvastatine Teva 10 mg - 80 mg tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ezetimibe/simvastatine teva 10 mg - 80 mg tabl.

teva pharma belgium sa-nv - simvastatin 80 mg; ezetimibe 10 mg - tablet - 10 mg - 80 mg - ezetimibe 10 mg; simvastatin 80 mg - simvastatin and ezetimibe

Ezetimibe/Simvastatine EG 10 mg - 80 mg tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ezetimibe/simvastatine eg 10 mg - 80 mg tabl.

eg sa-nv - ezetimibe 10 mg; simvastatin 80 mg - tablet - 10 mg - 80 mg - ezetimibe 10 mg; simvastatin 80 mg - simvastatin and ezetimibe

Ezetimibe/Simvastatine Viatris 10 mg - 80 mg tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ezetimibe/simvastatine viatris 10 mg - 80 mg tabl.

viatris gx bv-srl - simvastatin 80 mg; ezetimibe 10 mg - tablet - 10 mg - 80 mg - ezetimibe 10 mg; simvastatin 80 mg - simvastatin and ezetimibe